β-catenin, a vital multifunctional protein, plays a crucial role in maintaining physiological balance. Abnormal overexpression of β-catenin leads to various diseases, including cancer. In humans, the analogous gene to drosophila's armadillo is β-catenin, which serves as both an adapter protein for cell adhesion and a co-regulator of gene transcription.
The beta-catenin market is anticipated to experience growth due to an increase in the occurrence of genetic disorders. Similarly, market growth is expected to be driven by the rise in the approval of gene therapy drugs during the forecast period.
The projected worth of the global Beta-Catenin Market in 2022 is approximately US$ 2,492.0 million, with an anticipated compound annual growth rate (CAGR) of 9.6% from 2022 to 2030.
key Companies in the Beta-Catenin Industry:
Boston Biomedical, Inc.
Boston Biomedical Inc. was established in 2006 and is headquartered in Cambridge, Massachusetts, U.S. It is engaged in various industries, including biotechnology, healthcare, medical, and therapeutics.
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals Inc. was established in 2006 and is headquartered in Lexington, Massachusetts, U.S. It is engaged in various industries, including biotechnology, healthcare, genetics, and pharmaceuticals.
Marina Biotech, Inc.
Marina Biotech Inc. was established in 1983 and is headquartered in California, U.S. It is engaged in various industries, including biotechnology, healthcare, medical, and pharmaceuticals.
